ORZEYFUL (oveporexton) Gains Japanese Approval as the First and Only Medicine Addressing the Underlying Cause of Narcolepsy Type 1
Takeda has announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved ORZEYFUL (oveporexton) for the treatment of adults living with narcolepsy type 1 (NT1), also known as narcolepsy with cataplexy. The regulatory decision represents a significant milestone in the development of treatments for this rare neurological disorder and introduces a new therapeutic approach designed to address the underlying biological mechanism associated with NT1.
ORZEYFUL is a first-in-class oral orexin receptor 2 (OX2R) agonist and is the first medicine of its class to receive approval in Japan for NT1. According to Takeda, it is also the only medicine approved in Japan that is intended to address the disease more broadly rather than focusing primarily on individual symptoms. The discovery of the orexin agonist originated in Takeda’s research laboratories in Japan, highlighting the company’s efforts to translate internally generated scientific discoveries into medicines for patients.
Following the approval, Takeda is preparing for the commercial launch of ORZEYFUL in Japan and plans to make the medicine available to eligible patients as quickly as possible.
Julie Kim, president and chief executive officer of Takeda, described the approval as an important example of Japan-originated scientific innovation reaching patients. She emphasized that the discovery of the first orexin agonist represents a major achievement for Takeda’s research organization and could help reshape the treatment landscape for people living with NT1.
The approval is particularly significant because narcolepsy type 1 is associated with a deficiency of orexin, a neuropeptide system that plays an important role in regulating wakefulness, sleep and other physiological functions. Rather than simply targeting one symptom at a time, orexin receptor agonism is intended to restore signaling through the orexin pathway, potentially addressing several manifestations of the disease.
Understanding Narcolepsy Type 1
Narcolepsy type 1 is a chronic and rare neurological disorder characterized by excessive daytime sleepiness and cataplexy, a sudden and temporary loss of muscle tone that can be triggered by strong emotions such as laughter, excitement or surprise. The disease can affect patients throughout the day and night, creating challenges that extend well beyond daytime sleepiness.
People with NT1 may experience a combination of excessive daytime sleepiness, cataplexy, disrupted nighttime sleep, sleep paralysis, hallucinations and cognitive difficulties. Because these symptoms can vary considerably between individuals, the condition can be difficult to recognize and diagnose.
The persistent nature of NT1 can significantly interfere with everyday activities. Patients may experience difficulties at school or work, challenges with social interactions and limitations in their ability to participate in routine activities. The disease can therefore have a substantial impact on quality of life, productivity and independence.
Despite these effects, awareness of narcolepsy remains limited. The wide range of symptoms and similarities with other sleep or neurological conditions can contribute to delayed diagnosis or misdiagnosis. Patients may spend years seeking an explanation for their symptoms before receiving an accurate diagnosis. The average diagnostic delay has been reported to exceed 10 years, underscoring the continuing need for greater awareness and improved recognition of the disorder.
Targeting the Underlying Orexin Pathway
Historically, treatment strategies for narcolepsy have often concentrated on managing individual symptoms. For example, therapies may be used to improve daytime wakefulness or reduce the frequency and severity of cataplexy. While these approaches can provide meaningful benefits, they do not necessarily address the underlying orexin deficiency associated with NT1.
The development of orexin receptor agonists represents a different therapeutic strategy. Oveporexton is designed to selectively activate the orexin receptor 2 pathway. By stimulating OX2R, the medicine aims to reproduce some of the effects normally associated with orexin signaling.
This mechanism has generated considerable interest because the orexin system is closely involved in maintaining stable wakefulness and regulating sleep-wake states. Takeda’s development program has therefore focused on determining whether pharmacologically activating this pathway could improve multiple clinical manifestations of NT1.
Yuichi Inoue, professor in the Department of Somnology at Tokyo Medical University, noted that NT1 can affect patients around the clock and that advances in understanding the disease’s pathophysiology have opened opportunities for new therapeutic approaches. He highlighted the importance of expanding treatment options so physicians can select therapies according to the needs of individual patients.
Clinical Evidence Supporting the Approval
The Japanese approval of ORZEYFUL is supported by Takeda’s comprehensive clinical development program, including two global Phase 3 studies: FirstLight (TAK-861-3001) and RadiantLight (TAK-861-3002).
The studies evaluated the efficacy and safety of oveporexton in adults with narcolepsy type 1. According to Takeda, the clinical program demonstrated statistically significant improvements across the range of NT1 symptoms assessed.
The reported benefits included improvements in excessive daytime sleepiness and cataplexy, two of the most prominent and debilitating manifestations of NT1. Improvements were also observed across other secondary measures evaluated in the clinical studies, supporting the potential for oveporexton to have a broader impact on the disease rather than being limited to a single symptom.
The results from the Phase 3 program provide clinical support for Takeda’s approach of targeting the orexin pathway. The company believes these findings demonstrate the potential of OX2R agonism to provide a new therapeutic option for adults with NT1.
Oveporexton was generally well tolerated across the clinical development program, with Takeda reporting a consistent safety profile across studies conducted to date. The most frequently reported adverse events included insomnia, urinary urgency, urinary frequency and excessive salivation.
As with any newly approved medicine, physicians and patients will need to consider the complete prescribing information and safety profile when determining whether ORZEYFUL is appropriate for an individual patient.
A Milestone for Takeda’s Orexin Strategy
The Japanese approval also represents an important achievement for Takeda’s broader orexin research strategy. The company has invested in research aimed at understanding the orexin system and translating discoveries in this area into potential therapies.
Asuka Miyabashira, president of Takeda’s Japan Pharma Business Unit, credited the company’s scientists in Japan for their work in discovering a way to target the orexin deficiency associated with NT1. She described the achievement as a major scientific accomplishment and highlighted the significance of discovering, developing and preparing to commercialize a new medicine internally.
The development of ORZEYFUL demonstrates the progression of a research concept from laboratory discovery through clinical development and regulatory approval. For Takeda, the milestone also reinforces the role of its Japanese research capabilities in contributing to its global pharmaceutical pipeline.
The company has worked with healthcare professionals, researchers and the patient community throughout the development process. The Japanese launch will now represent the next stage in bringing the therapy to adults who may benefit from an orexin-based treatment approach.
Expanding Global Access to Oveporexton
The MHLW decision marks the third regulatory approval for ORZEYFUL globally. The medicine has also received approval for NT1 in China and the United States.
In the U.S., the controlled substance classification of ORZEYFUL remains under review by the U.S. Drug Enforcement Administration. The outcome of that process is an important component of the U.S. commercialization pathway and could influence how the medicine becomes available to patients and healthcare providers in that market.
With approvals now extending across multiple major markets, Takeda is continuing to advance its global commercialization plans for oveporexton. Japan’s approval is particularly notable because the drug’s discovery originated in the country and the Japanese regulatory decision brings the treatment back to the market where the underlying scientific work began.
Potential Impact on Narcolepsy Care
The approval of ORZEYFUL could represent an important shift in how narcolepsy type 1 is approached therapeutically. By targeting the orexin pathway, oveporexton is designed to address a fundamental biological feature of NT1 rather than focusing exclusively on individual symptoms.
For patients, the availability of an oral OX2R agonist could provide another option within an evolving treatment landscape. The ability to improve multiple manifestations of NT1 may also offer physicians additional flexibility when developing individualized treatment strategies.
However, broader awareness and earlier diagnosis remain important challenges. Even as new medicines become available, patients cannot benefit from appropriate treatment unless the disease is recognized and diagnosed. Greater education among healthcare professionals and the public could help reduce the lengthy diagnostic journey experienced by many people with narcolepsy.
Takeda’s Japanese approval of ORZEYFUL therefore represents more than the introduction of another treatment option. It marks the clinical translation of decades of scientific work focused on the orexin system and provides further validation for a therapeutic strategy aimed at the underlying biology of narcolepsy type 1.
As Takeda moves forward with launch preparations in Japan, the company is expected to focus on making ORZEYFUL available to appropriate adult patients while continuing to build its broader global presence. The approval also underscores the potential of Japan-originated biomedical research to produce innovative medicines with international relevance.
For adults living with narcolepsy type 1, healthcare providers and researchers, the arrival of an OX2R agonist provides a new chapter in the treatment of a condition that can affect virtually every aspect of daily life. With ORZEYFUL now approved in Japan, Takeda’s orexin strategy has reached a significant regulatory milestone and may contribute to a broader transformation in how NT1 is understood and treated.
About ORZEYFUL (Oveporexton)
ORZEYFUL (oveporexton) is an oral orexin receptor 2 (OX2R) agonist, which selectively stimulates the OX2R to restore signaling and address the underlying orexin deficiency associated with narcolepsy type 1 (NT1). By activating OX2Rs, ORZEYFUL promotes wakefulness and reduces abnormal rapid eye movement (REM)-sleep like phenomena, including cataplexy (sudden and temporary loss of muscle tone), to address a range of daytime and nighttime symptoms as evaluated in clinical studies and consistent with the approved label.
About Takeda’s Orexin Franchise
Takeda is the leader in orexin science with a tailored portfolio of investigational orexin agonists in pre-clinical and clinical stages for multiple-sleep wake disorders and other indications where orexin plays a role including respiration, mood and metabolism. Oveporexton is the lead orexin receptor 2 (OX2R) agonist in Takeda’s orexin franchise and has been approved by regulatory bodies in China for the treatment of narcolepsy type 1 (NT1) in adolescents aged 16 and older and adults as well as in the United States and Japan for adults with NT1. The company is also investigating other oral orexin agonists, including TAK-360 for the treatment of NT1, narcolepsy type 2 (NT2) and idiopathic hypersomnia (IH), as well as TAK-495.
About Takeda
Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline.
As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com.